PPA
GALT icon

Parametric Portfolio Associates’s Galectin Therapeutics GALT Stock Holding History

Parametric Portfolio Associates’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-31,086
Closed -$121K – 3662
2021
Q3 		$121K Sell
31,086
-24,961
-45% -$84.6K ﹤0.01% 3510
2021
Q2 		$179K Buy
56,047
+21,640
+63% +$77K ﹤0.01% 3425
2021
Q1 		$75K Buy
34,407
+21,660
+170% +$48.5K ﹤0.01% 3995
2020
Q4 		$29K Sell
12,747
-313
-2% -$821 ﹤0.01% 3967
2020
Q3 		$35K Buy
13,060
+56
+0.4% +$157 ﹤0.01% 3893
2020
Q2 		$40K Buy
+13,004
New +$32.7K ﹤0.01% 3878
2015
Q3 		– Sell
-11,613
Closed -$32K – 3291
2015
Q2 		$32K Sell
11,613
-2,265
-16% -$6.83K ﹤0.01% 3941
2015
Q1 		$46K Buy
13,878
+3,731
+37% +$13.3K ﹤0.01% 3908
2014
Q4 		$35K Sell
10,147
-1,536
-13% -$6.79K ﹤0.01% 3962
2014
Q3 		$59K Buy
+11,683
New +$91K ﹤0.01% 3768

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parametric Portfolio Associates's GALT Position: Q4 2021 in Review

Parametric Portfolio Associates sold out of Galectin Therapeutics (GALT) in Q4 2021, closing a stake of 31,086 shares — an estimated $121K sold.

Parametric Portfolio Associates first reported a position in GALT in Q3 2014 and held it in 10 quarters. The position peaked at $179K in Q2 2021. 55 funds tracked by Wall St. Rank hold GALT as of Q4 2021.

  • Parametric Portfolio Associates reported no remaining Galectin Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 31,086 Galectin Therapeutics shares in Q4 2021, an estimated $121K.
  • Parametric Portfolio Associates first reported a position in Galectin Therapeutics in Q3 2014 and held it in 10 quarters.
  • Parametric Portfolio Associates's Galectin Therapeutics position peaked at $179K in Q2 2021.
  • 55 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2021.

Based on Parametric Portfolio Associates's 13F filing for Q4 2021, filed 15 Feb 2022.